<DOC>
	<DOCNO>NCT00739167</DOCNO>
	<brief_summary>RATIONALE : Learning quality life patient cancer undergo embolization may help doctor learn side effect treatment plan best treatment . PURPOSE : This clinical trial study quality life patient undergoing embolization use yttrium Y 90 glass microspheres primary metastatic liver cancer .</brief_summary>
	<brief_title>Quality Life Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres Primary Metastatic Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess quality life ( QOL ) define presence absence physical , social , emotional , functional distress patient primary metastatic liver cancer undergo treatment radioembolization transcatheter arterial embolization . - Compare time course QOL measure treatment group patient treat regimen . - Compare time course QOL measure patient subgroup define pre-treatment quality life tumor burden . OUTLINE : Patients complete FACT-Hep version 4 survey quality life prior initiation embolization , 2 week 1 month completion embolization .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary hepatocellular cancer metastatic liver cancer Planning radioembolization transcatheter arterial embolization use yttrium Y 90 glass microspheres No encephalopathy PATIENT CHARACTERISTICS : ECOG performance status 02 Bilirubin â‰¤ 3 mg/dL Able comply study procedure PRIOR CONCURRENT THERAPY : No prior treatment radioembolization transcatheter arterial embolization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>